SO-21 Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study)

Abstract

BRAF mutations occur in up to 15% of patients with metastatic colorectal cancer (mCRC) and the BRAF V600E mutation is a marker of poor prognosis. Inhibition of BRAF alone has not demonstrated clinical activity due to rapid feedback activation of EGFR that supports continued proliferation of BRAF V600E-mutated CRC tumor cells. In the BEACON CRC study, both triplet therapy with encorafenib (BRAF inhibitor) + binimetinib (MEK inhibitor) + cetuximab (epidermal growth factor receptor inhibitor), and doublet therapy with encorafenib + cetuximab demonstrated improved overall survival (OS) and objective response in patients with BRAF V600E mCRC compared with current standard of care (median OS: 9.3 months [triplet] and 9.3 months [doublet] vs 5.9 months [control]; objective response rate: 27% [triplet] and 20% [doublet] vs 2% [control], p< 0.0001 for both).